Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
William Barbour(Western University), Subodh Verma(St. Michael's Hospital), Andrew T. Yan(St. Michael's Hospital), C. David Mazer(St. Michael's Hospital), Hwee Teoh(St. Michael's Hospital), Ehab Bakbak(The University of Queensland), Aishwarya Krishnaraj(St. Michael's Hospital), Pankaj Puar(St. Michael's Hospital), Adrian Quan(St. Michael's Hospital), Erika M. Wolff(Howard Hughes Medical Institute), Meena Verma(St. Michael's Hospital), Raj Verma(Royal College of Surgeons in Ireland), Kim A. Connelly(St. Michael's Hospital), Makoto Hibino(St. Michael's Hospital)
Cited by 2
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Identification of deletion mutations and three new genes at the familial polyposis locus
|Cell|1991|768
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733